People: Roche Holding AG (RHHVF.PK)

Summary

Name	Age	Since	Current Position
Severin Schwan	46	2008	Chairman of the Corporate Executive Committee, Chief Executive Officer
Fritz Gerber	84	2004	Honorary Chairman of the Board
Franz Humer	66	2008	Non-Executive Chairman of the Board of Directors
Bruno Gehrig	66	2008	Non-Executive Vice Chairman of the Board
Andre Hoffmann	54		Non-Executive Vice Chairman of the Board
Alan Hippe	46	2011	Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Stephan Feldhaus	51	2010	Member of the Enlarged Corporate Executive Committee, Head Group Communications
Sophie Kornowski-Bonnet	49	2012	Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Osamu Nagayama	66	1992	Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
John Reed	55	2013	Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Richard Scheller	60	2009	Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Urs Jaisli	57		Chief Compliance Officer
Gottlieb Keller	59	2008	Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Silvia Ayyoubi	60	2008	Member of the Corporate Executive Committee, Head of Group Human Resources
Roland Diggelmann	46	2012	Member of the Executive Committee, Chief Operating Officer of the Division Roche Diagnostics
Daniel O'Day	48	2010	Member of the Corporate Executive Committee, Chief Operating Officer of the Diagnostics Division
Per-Olof Attinger	53	2010	Secretary to the Corporate Executive Committee, Head CEO Office
Pius Baschera	62	2007	Non-Executive Director
John Bell	60	2001	Non-Executive Director
Paul Bulcke	59	2011	Non-Executive Director
William Burns	65	2010	Non-Executive Director
Lodewijk de Vink	68	2004	Non-Executive Director
Christoph Franz	53	2011	Non-Executive Director
DeAnne Julius	64	2002	Non-Executive Director
Arthur Levinson	63	2010	Non-Executive Director
Andreas Oeri	64	1996	Non-Executive Director
Peter Voser	54	2011	Non-Executive Director
Beatrice Weder di Mauro	47	2006	Non-Executive Director
F. Hoffmann			IR Contact Officer

» Insider Trading

Biographies

Name	Description
Severin Schwan	Dr. Severin Schwan has been Chairman of the Corporate Executive Committee and Chief Executive Officer of Roche Holding AG since March 4, 2008. He was previously CEO of the Division Roche Diagnostics and Member of the Corporate Executive Committee at the Company from January 1, 2006. Between 1993 and 1995, he was a Trainee at Corporate Finance for Roche Basel. From 1995 until 1998, he was Head of Finance & Administration at Roche Brussels. From 1998 until 2000, Dr. Schwan was Head Finance & Informatics at Roche Grenzach, Germany and Member of the Executive Board of Roche Deutschland Holding GmbH. From 2000 until 2004, he was Head of Global Finance & Services at Roche Diagnostics, Basel. Since 2009, Dr. Schwan has been Member of the Board of Directors of Chugai Pharmaceuticals, Japan, and Member of the International Business Leaders Advisory Council for the Mayor of Shanghai (IBLAC). Dr. Schwan studied Economics at Universitaet Innsbruck, University of York and University of Oxford. He gained an Economics Degree from Innsbruck. He studied Law at Universitaet Innsbruck and gained a Law degree in 1991. Dr. Schwan then completed a Doctorate in Law at Universitaet Innsbruck in 1993 and Research studies at Universite Catholiques de Louvaine, Belgium.
Fritz Gerber	Dr. Fritz Gerber has been Honorary Chairman of the Board at Roche Holding AG since 2001. Between 2001 and 2004, he additionally acted as Company's Member of the Board of Directors. From 1978 to 1997 Dr. Gerber occupied the position of Chairman of the Board at Roche Holding Ltd. and was also active as Chief Executive Officer between 1978 and 1997. Dr. Gerber has worked in the Federal Department of Economic Affairs, Bern (now SECO). In 1958, he joined "Zuerich" Insurance Company (now Zurich Financial Services), where he became General Manager in 1969 and Chairman of the Management Board in 1974. From 1977 until 1991, Dr. Gerber was Chairman of the Board of Directors and Chief Executive Officer and from 1991 until 1995, he was Non-Executive Chairman of the Board of Directors. Since 1995, he has been Honorary Chairman of Zurich Financial Services. From 1978 until 1997, he was Chairman of the Board of Directors and Chief Executive Officer of F. Hoffmann-La Roche & Co. Ltd. (now: Roche Holding Ltd.). From 1978 until 2001, Dr. Gerber was Chairman of the Board of Directors and from 2001 until 2004, he was Member of the Board of Directors and Honorary Chairman. He has also served as Member of the Board of I.C.I. Switzerland from 1967 until 1991, Alusuisse, Zuerich from 1977 until 1981, Credit Suisse, Zuerich, from 1978 until 1996, Nestle, Vevey (Deputy Chairman of the Board) from 1981 until 2001, IBM Corporation, Armonk from 1989 until 1996 and Bank Sal. Oppenheim jr., Zurich from 1997 until 2005. He served as Chairman of the Paul Sacher Foundation for contemporary music until April 2006, was Member of the Executive Committee of the Lucerne Music Festival until 2004 and Member of the Orchesterakademie des Philharmonischen Orchesters Berlin until 2004. Dr. Gerber is also Honorary Chairman of the Fritz Gerber Foundation. He studied at Universitaet Bern and graduated as Lawyer (LL.M) and was admitted to the bar. He is an Honorary Doctor of Natural Science of Universitaet Basel, Switzerland.
Franz Humer	Dr. Franz B. Humer has been Non-Executive Chairman of the Board of Directors of Roche Holding AG since March 4, 2008. In addition, he acts as Chairman of the Presidium/Nomination Committee of the Company. From 2001 until March 4, 2008, Dr. Humer served as Chairman of the Corporate Executive Committee and Chief Executive Officer (CEO) at Roche Holding Ltd. From 1971 to 1973, Dr. Humer worked for ICME Zurich. From 1973 until 1981, he worked for Schering Plough Corporation, where he was General Manager in Ecuador, the United Kingdom and Portugal. From 1981 until 1995, Dr. Humer worked for Glaxo Holdings plc as Area Manager, Southern Europe, Director of Marketing Development and Product Licensing, and Chief Operating Director. In 1995, he joined F. Hoffmann-La Roche Ltd as Member of the Board of Directors of the Roche Holding Ltd, Basel, and Head of the Pharmaceuticals Division. In 1996, he became Chief Operating Officer of F. Hoffmann-La Roche Ltd. In 1998, Dr. Humer became CEO Roche Holding Ltd. He is Member of the European Round Table of Industrialists (ERT), Member of the JPMorgan International Council, Board Member of Salzburg University and Member of the Advisory Board at Allianz AG. Furthermore, Dr. Humer occupies the position of Vice Chairman of the International Advisory Board at the International Center for Missing and Exploited Children, Non-Executive Chairman at Diageo Plc and Chairman at Humer Stiftung as well as INSEAD. He holds a Doctorate degree in Law from Universitaet Innsbruck and a Master of Business Administration degree from Institut Europeen d'Administration des Affaires (INSEAD). He also holds an Honorary Doctorate from the Faculty of Science, Universitaet Basel.
Bruno Gehrig	Prof. Dr. Bruno Gehrig has been Non-Executive Vice Chairman of the Board of Directors of Roche Holding AG since March 4, 2008. In addition, he acts as Chairman of the Remuneration Committee and as Member of the Presidium/Nomination Committee of the Company. Prior to that, from Apriil 6, 2004 to March 4, 2008, he also served as Independent Lead Director of the Company. From 1989 until 1991, Prof. Dr. Gehrig occupied the position of Chairman of the Executive Board of Bank Cantrade Ltd., Zurich, with responsibility for the other parts of the group. From 1992 until 1996, he was active as Professor of Business Administration at the University of St. Gallen and Head of its Swiss Institute Banking and Finance. From 1996 until 2000, he was Member of the Governing Board of the Swiss National Bank. From 2001 until 2003, Prof. Dr. Gehrig was Vice Chairman of the Governing Board of the Swiss National Bank. Since July 2003, he has been Chairman of the Board of Directors of Swiss Life Holding. From 1971 until 1980, he was Assistant and, from 1978, Lecturer at the University of Bern. In 1975, he gained a Doctorate in Economics (Dr. rer. pol.) from Universitaet Bern. In 1978, Prof. Dr. Gehrig qualified as Lecturer at Universitaet Bern with a study on Monetary Policy, following studies with Prof. Karl Brunner at the University of Rochester. In 2006, he received an Honorary Doctorate of Laws from the University of Rochester. From 1984 until 1991, he was Chairman of the economic policy study group of the Christian Democratic Party (CVP) and from 1992 until 1996, he was Member of the Swiss Federal Banking Commission. Currently Prof. Dr. Gehrig serves as Member of the Board of Trustees of Kartause Ittingen, Canton of Thurgau, Switzerland; Chairman of the Board of Trustees of the Swiss Air Transport Foundation and Member of the Board of Trustees of the Foundation Antidoping Schweiz. Moreover, he is Member of the Board of Directors at UBS AG.
Andre Hoffmann	Mr. Andre Hoffmann is Non-Executive Vice Chairman of the Board of Directors at Roche Holding AG. He also acts as Member of the Presidium/Nomination Committee, Corporate Governance and Sustainability Committee, as well as Remuneration Committee of the Company. He joined the Company’s Board of Directors in 1996. From 1977 until 1978, he studied at Universite de Geneve and from 1979 until 1982 he studied at St. Gallen School. In 1990, he received a Master of Business Administration degree from Institut Europeen d’Administration des Affaires (INSEAD). From 1985 until 1989, he worked for James Capel and Co., where his latest position was Manager, European Mergers & Acquisitions. From 1991 until 1993, he worked for Nestle UK Ltd., where his latest position was Special Project Manager, Food division. Since 1994, he worked in Private Investment Activities. Since 2000, he has been Member of the Board of Givaudan Ltd., Member of the Board of Glyndebourne Productions Ltd., and Chairman of Nemadi Advisors Ltd. Since 2003, he has been Member of the Board of Brunswick Capital Ltd. and Chairman of Living Planet Fund Management Co. He is Vice President of WWF International, Treasurer of Fondation les Corbillettes pour l'Aide aux enfants handicapes mentaux, Member of the Executive Committee of IRP, Institut International de Recherche en Paraplegie, Founding Member of Stiftung Patronatskomitee Kunstmuseum Basel, Board Member of Roche Research Foundation, International Council Member of Tate Gallery, Chairman of the Board of Fondation Pro Valat, Vice Chairman of the Board of Fondation Sansouire, Board Member of Takh, Association pour le Cheval de Przewalski, President of FIBA, Fondation Internationale du Banc d'Arguin, among others.
Alan Hippe	Dr. Alan Hippe has been Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer at Roche Holding AG since April 1, 2011. Between 1993 and 1996 Dr. Hippe was Research Assistant and Teaching Assistant at the Universities of Mainz and Mannheim. In 1996 he joined AVECO Holding AG as Head of group controlling and IT systems. He served as Member of the Executive Board of Continental AG from 2002 to 2009. Since April 2009 he has been Chief Financial Officer and Member of Executive Board of ThyssenKrupp AG.
Stephan Feldhaus	Dr. Stephan Feldhaus has been Member of the Enlarged Corporate Executive Committee and Head Group Communications at Roche Holding AG since August 1, 2010. He studied Roman Catholic Theology and Philosophy at Roman University of Muenster, Universitaet Zuerich and Lucerne and Ludwig-Maximilians-Universitaet Muenchen (University of Munich) and obtained his Doctorate in Theology (Dr. theol.) at the University of Munich in 1997. He started his career at Ludwig-Maximilians-Universitaet Muenchen (the University of Munich) as Scientific Assistant in 1989. He than worked for Cusanus Werk (Academic Foundation of the German bishops) as Scientific Assistant and Editor. In 1999, he joined Siemens AG.
Sophie Kornowski-Bonnet	Dr. Sophie Kornowski-Bonnet has been Member of the Enlarged Corporate Executive Committee and Head of Roche Partnering at Roche Holding AG since February 1, 2012. She received an MBA in Marketing/Finance from the University of chicago in 1989 and a PhD in Pharmacy in 1986. Dr. Kornowski-Bonnet started her career in 1985 as Scientific Manager in Abbott Diagnostic Division. She held this position until 1987. In 1989 she moved on to become Marketing Research Analyst, Neuroscience Sales Representative for Abbott Pharmaceutical Products in Chicago. Between 1991 and 1994, she was Director, Strategic Marketing, Diagnostic Imaging at Sanofi Winthrop, after which she switched to the position of Director, Neuroscience Business Unit there. In 1996 Dr. Kornowski-Bonnet assumed the position of Director, Marketing Research and Strategic Planning at Merck Sharp & Dohme, and in 1997 was promoted to Managing Director there. From 2000 to 2002, she was Vice-President Arthritis and Analgesia Franchise at Merck & Co. Inc, where she held various positions within the following years. Dr. Kornowski-Bonnet joined the Roche group in 2007 as General Manager.
Osamu Nagayama	Mr. Osamu Nagayama has been Member of the Enlarged Corporate Executive Committee and President and Chief Executive Officer of Chugai at Roche Holding AG since 1992. Mr. Nagayama started his professional careeer in 1971 at the Long-Term Credit Bank of Japan. He joined Chugai Pharmaceutical Co. Ltd in 1978 and became its President in 1992. He studied at the Faculty of Business and Commerce at Keio University.
John Reed	Dr. John C. Reed has been appointed Member of the Enlarged Corporate Executive Committee and Head of Roche Pharma Research & Early Development at Roche Holding AG with effect from April 2, 2013. He graduated from University of Virginia with B.A. degree in 1980. Moreover, he gained his M.D. and Ph.D. degrees at the University of Pennsylvania, School of Medicine, Philadelphia, the United States.
Richard Scheller	Dr. Richard H. Scheller has been Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development at Roche Holding AG since 2009. Dr. Scheller started his professional career at the California Institute of Technology at the Division of Biology. From 1981, he worked at the Columbia University and switched to the Stanford University in 1982. He joined Genetech as Senior Vice President Research. He received his Bachelor of Science at the Department of Biochemistry from the University of Wisconsin in 1975 and Ph.D. in Chemistry from the California Institute of Technology in 1980.
Urs Jaisli
Gottlieb Keller	Dr. Gottlieb A. Keller has been Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors at Roche Holding AG since March 5, 2008. He was previously Head of Human Resources and Corporate Services, as well as Secretary to the Board of Directors and Member of Corporate Executive Committee at the Company as of 2004. In 1984, he joined the Corporate Law Department of the Roche Group. In 1989, he became Head of Business Development and Pharma Marketing Services of Roche Grenzach, Germany. In 1992, he became Assistant to the Chairman of the Board of Directors of Roche Holding Ltd. In 1996, he became Head of Human Resources at Hoffmann-La Roche Ltd, Germany. In 1998, he became Speaker of the Management Board of Hoffmann-La Roche Ltd, Germany. In 1999, he became Chairman of the Executive Board of Roche Deutschland Holding GmbH and then Secretary to the Board of Directors of Roche Holding Ltd and Corporate Compliance Officer of the Roche Group. In 2003, he became Member of the Corporate Executive Committee of the Roche Group and Head of Corporate Human Resources and Pharma Site Management in Basel and Kaiseraugst. In 2004, he became Head of Corporate Services and Human Resources. He is Committee Member of VSUD, President of the Board of Crocodil AG, Member of the Chairman's Committee of the Chamber of Commerce Germany-Switzerland, Member of the Board of Trustees of the Fritz Gerber Foundation for talented young people, Member of the Board of Trustees of the Paul Sacher Foundation and of swisscontact and Board Member of SGCI Chemie Pharma Schweiz and of economiesuisse. From 2003 until 2008, he was Board Member of the Basilea Pharmaceutica AG. Dr. Keller studied Law and Economics at Universitaet Basel and gained a Doctor of Law (Dr. iur) in 1980. He was admitted as Attorney in 1981 and became Notary Public of Basel in 1984 (not practicing).
Silvia Ayyoubi	Ms. Silvia Ayyoubi has been Member of the Corporate Executive Committee and Head of Group Human Resources at Roche Holding AG since March 5, 2008. From 1974, she worked for the Swiss Ministry of Foreign Affairs in Switzerland, Sweden, Egypt and Jordan. As of 1986, she acted for Effifreight in Basel. She switched to F. Hoffmann-La Roche Ltd in Basel in 1987, where she was active as Public Relations Assistant, Pharma Communications. From 1989, she held the position of Public Relations and Issue Manager. From 1991, she worked as Head of Executive Resource Planning Pharma in Corporate Human Resources. From 1996, she served as Head of Executive Development in Corporate Human Resources. From 2001, she occupied the position of Head of Global Human Resources in the Diagnostics Division. She holds a Diploma in Commercial Economics from the Business School in Basel.
Roland Diggelmann	Mr. Roland Diggelmann has served as Member of the Executive Committee, Chief Operating Officer of the Division Roche Diagnostics of Roche Holding AG since September 1, 2012. He studied Aministration at the University of Berne. Mr. Diggelmann started his career in 1995 by joining AlloPro AG as Manager Strategic Planning. In 1997 he switched to Sulzer Orthopedics Ltd, where he assumed the position of Director Strategic Planning & Marketing. In 1999 he became Executive VP Strategic Planning & Marketing there, and in 2001 - Executive VP Sales Asia Pacific. In 2002 Mr. Diggelmann was appointed Executive VP Sales Europe and Asia Pacific at Sulzer Medica/Centerpulse Ltd. In 2004, he became Senior VP Sales / Distribution EMEA and Managing Director at Zimmer GmbH. He joined the Company in 2008 as Head Region Asia Pacific.
Daniel O'Day	Mr. Daniel O'Day has been Member of the Corporate Executive Committee, Chief Operating Officer of the Diagnostics Division at Roche Holding AG since Janaury 1, 2010. From 1987 to 1995 he held various commercial and sales roles at Roche Pharma in the United States, becoming Director of Human Resources in 1995. From 1996 he was Director of Product Marketing at Roche Pharma in the United States. From 1998 he worked for Roche Pharma HQ in Switzerland. From 2001 he acted at Roche Pharma in Japan as Head of Corporate Planning. In 2003 he became General Manager at Roche Pharma in Denmark. Since 2006, he has been President and Chief Executive Officer of Roche Molecular Diagnostics in the United States. He received a Bachelor of Science in Biology from the Georgetown University, Washington DC in 1986 and an MBA from Columbia University, New York in 1997.
Per-Olof Attinger	Mr. Per-Olof Attinger has been Secretary to the Corporate Executive Committee and Head CEO Office at Roche Holding AG since August 1, 2010. Mr. Attinger started his professional career in 1986 at Sandoz as Engineer responsible for Chemical Process Development. He has served at Roche since 1992, where he has occupied various managerial positons, including Manager of Mergers & Acquisitions, among others. In 1984, he obtained a degree in Chemical Engineering from the Federal Institute of Technology (ETH) Zurich. He than made Thesis at Imperial College in London and received his Masters degree in Busines Administration from European Institute for Business Administration (INSEAD) in 1992.
Pius Baschera	Prof. Dr. Pius Baschera has been Non-Executive Director at Roche Holding AG since March 5, 2007. He is Member of the Corporate Governance and Sustainability Committee of the Company. From 1979 to 1981, Prof. Dr. Baschera was Vice President Production Controlling at Hilti Corporation, Schaan, and from 1982 to 1984 he was Vice President Corporate Development Western Hemisphere at Hilti Inc. Tulsa, in the United States of America. In 1985, he became General Manager of Hilti (Switzerland) AG and from 1985 until 1989, General Manager of Hilti Deutschland GmbH. From 1989 until 1990, Prof. Dr. Baschera was Vice President Market Region Europe 1 at Hilti Corporation, Schaan, where he then worked as Member of Executive Board and Chief Financial Officer from 1990 until 1993 and Chief Executive Officer from 1994 until 2006. He then became Hilti Corporation’s Chairman of the Board of Directors in 2007. Prof. Dr. Baschera also serves as Member of Advisory Board of Vorwerk and Ardex GmbH, as Chairman of the Board of Directors of Venture Incubator AG and as Member of Board of Directors of Schindler Holding AG. He studied Mechanical Engineering with Scientific Management at the Swiss Federal Institute of Technology in Zurich, where he gained a Doctorate and became Titular Professor.
John Bell	Prof. Sir John Irving Bell has been Non-Executive Director of Roche Holding AG since 2001. In addition, he acts as Member of the Audit Committee of the Company. In 1975, he gained a Bachelor of Medical Science with Honors from the University of Alberta. In 1976, Prof. Sir Bell gained a Bachelor of Arts with Honors in Physiological Sciences from Magdalen College, Oxford University. In 1979, he gained a Bachelor of Medicine and Bachelor of Surgery (BM, BCh) from Magdalen College, Oxford University. In 1990, he gained a Doctor of Medicine (DM) from Magdalen College, Oxford University. From 1979 until 1982, he carried out postgraduate clinical training in Oxford and London. From 1982 until 1987, Prof. Sir Bell was Clinical Fellow in the Department of Medicine at Stanford University and also Postdoctoral Fellow in the Department of Medical Microbiology at Stanford University. From 1987 until 1989, he was Wellcome Senior Clinical Fellow and Honorary Consultant Physician in the Nuffield Departments of Clinical Medicine and Surgery at John Radcliffe Hospital, Oxford. From 1989 until 1992, he was University Lecturer at the Nuffield Department of Clinical Medicine at Oxford University. From 1992 until 2002, he was Nuffield Professor of Clinical Medicine at Oxford University. Since 2002, Prof. Sir Bell has been Regius Professor of Medicine at Oxford University. He is also has been Honorary Consultant Physician at Oxford Radcliffe NHS Trust since 1987; Nuffield Professor of Clinical Medicine Chairman at the Department of Medicine, Oxford University School of Medicine, since 1992; Founder of the Wellcome Trust Centre for Human Genetics since 1993; Chairman of the Partnership Board at the Oxford Centre for Diabetes, Endocrinology and Metabolism since 1999; Chairman of the Trials and Epidemiology Building, Oxford since 1999; and President of the Academy of Medical Sciences since 2006. He was knighted in the 2008 Honors list for Services to Medicine.
Paul Bulcke	Mr. Paul Bulcke has been Non-Executive Director at Roche Holding AG since March 1, 2011. He is Member of the Audit Committee at the Company. He started his career in 1977 as Financial Analyst with Scott Graphics International. In 1979 he joined Nestle Group where he held several position including Marketing trainee, sales and division functions, Market Head at Nestle Portugal, Nestle Chech and Slovak Republic, as well as at Nestle Germany. Between 2004 and 2008, Mr. Bulcke acted as Executive Vice President, Nestle S.A. as well as Zone Director for Zone Americas: United States of America, Canada, Latin America and Caribbean. Mr. Bulcke has been Chief Executive Officer of Nestle S.A. since April 2008. He studied Commercial Engineering at Katholieke Universiteit Leuven, from which he graduated in 1976. Between 1976 and 1977 he attended postgraduate studies in Management at Vlerick Leuven Gent Management School, and in 1995 he completed Program for Executive Development at Institute of Management Development (IMD) Switzerland.
William Burns	Mr. William M. Burns has been Non-Executive Director at Roche Holding AG since March 2, 2010. He is Member of the Audit Committee at the Company. Prior to assuming this role, he was CEO Division Roche Pharmaceuticals and Member of the Corporate Executive from January 1, 2005 to December 31, 2009 and before that - Member of the Corporate Executive Committee, Head of Pharmaceuticals Division between 2001 and 2005. He joined the Company’s executive team in 2000 as Member of the Corporate Executive Committee. Mr. Burns started his career in 1969 with Beecham Pharmaceuticals. In 1986, he became Director of Sales and Marketing for Roche UK. In 1988, he became Head of Pharmaceuticals Division at Roche UK, and in 1991 Global Head of Strategic Marketing and Business Development at F. Hoffmann-La Roche Ltd, Basel. In 1998, Mr. Burns became Head of Europe/International. In 2002, Mr. Burns became Board Member of Chugai Pharmaceuticals, Japan, a Subsidiary of the Roche Group. In 2004, he became Board Member of Genentech, United States of America, another Roche Subsidiary. Mr. Burns is Member of the Board of Directors at Shire PLC. He studied at the University of Strathclyde, where he gained a Bachelor of Art (Honors Degree).
Lodewijk de Vink	Mr. Lodewijk J. R. de Vink has been Non-Executive Director at Roche Holding AG since May 6, 2004. In addition, he acts as Member of the Remuneration Committee of the Company. In 1968 Mr. de Vink earned a Bachelor of Business Administration degree from Washburn University and in 1969 a Master of Business Administration degree from American University. From 1969 until 1988, he worked for Schering-Plough/Schering International. From 1988 until 2000, he worked for Warner-Lambert Company, where he was Chairman of the Board, President and Chief Executive Officer between 1999 and 2000. Between 2000 and 2002, Mr. de Vink was Chairman of Global Health Care Partners at Credit Suisse First Boston. From 2002 until 2003, Mr. de Vink was Chairman of International Health Care Partners. Since 2003, he has been Founding Member and Consultant at Blackstone Healthcare Partners, LLC. He served as Board Member of Pharmaceutical Research and Manufacturers of America (PhRMA) where he was Chairman in 1995; The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) where he was Chairman from 1998 until 1999;Trilateral Commission; The Business Roundtable; The French American Business Council, and Royal Ahold. He was United States Chair of the 1998 TransAtlantic Business Dialogue (TABD) and in 1990 was appointed to the President's Export Council. Currently, Mr. de Vink serves as Member of Sotheby's International Advisory Board, Member of the Board of Alcon, Inc., Member of European Advisory Council of Rothschild & Cie., Member of the Board of Flamel Technologies and Member of the Board of Stiefel Laboratories Inc.
Christoph Franz	Dr. Christoph Franz has been Non-Executive Director of Roche Holding AG since March 1, 2011. He is Member of the Remuneration Committee at the Company. He began his career in 1991 with Deutsche Lufthansa AG. In 1994 he joined Deutsche Bahn AG and acted as Member of the Executive Board and CEO of passenger transport division. In 2004 he became Chief Executive Officer of Swiss International Air Lines AG. In 2009 Dr. Franz became Member of the Executive Board of Deutsche Lufthansa AG and Deputy to the Executive Board Chairman and CEO Lufthansa Passenger Airlines. Since January 2011 he has been Chairman of the Executive Board and Chief Executive Officer of Deutsche Lufthansa AG. He holds a Doctorate degree (Dr. rer. pol.) from Technische Universitaet Darmstadt (Darmstadt Technical University).
DeAnne Julius	Dr. DeAnne S. Julius has been Non-Executive Director at Roche Holding AG since 2002. In addition, she acts as Chairwoman of the Audit Committee of the Company. From 1970 until 1971, she was Economic Analyst the United States Government Civil Service, Washington DC. From 1972 until1975, she was Lecturer and Teaching Assistant at the University of California. From 1975 until 1982, Dr. Julius was Economic Advisor at the World Bank, Washington DC, and between 1983 and 1986, she was Managing Director at Logan Associates Inc, Washington DC and London. From 1986 until 1989, she was Director of the International Economics Program at the Royal Institute of International Affairs (Chatham House), London. From 1989 until 1993, she was Chief Economist at the Royal Dutch Shell Group, London. Between 1993 and 1997, Dr. Julius was Chief Economist at British Airways PLC, London. From 1997 until 2001, she was Member of the Monetary Policy Committee of the Bank of England. From 2001 until 2004, she was Member of the Court of Bank of England. Since 2003, Dr. Julius has been Chairman of the Royal Institute of International Affairs. Moreover, she is also Non-Executive Director of BP, Vice President of the Society of Business Economists and Non-Executive Member of the Board of Directors of Jones Lang LaSalle Inc. She holds a Master of Arts degree as well as a Doctorate (Ph.D.) degree in Economics from the University of California and a Bachelor of Science degree in Economics from Iowa State University. Dr. Julius also holds Honorary Degrees from the University of Warwick, the University of Birmingham, Southbank University and the University of Bath (United Kingdom).
Arthur Levinson	Dr. Arthur D. (Art) Levinson has been Non-Executive Director at Roche Holding AG since March 2, 2010. He also acts as Member of the Remuneration Committee at the Company. He occupies the position of Chairman of the Board of Directors at Genentech, Inc. In 1977 he gained a Doctorate in Philosophy degree in Biochemistry from Princeton University and in 1972 a Bachelor of Science degree in Molecular Biology from University of Washington. He started his career in 1977 at the University of California in San Francisco, at the Department of Microbiology. Since 1980 he has worked for Genetech Inc, where he occupied several positions, most recently as Chairman from 2009. He is Member of the Board of Directors at Apple Inc, Google Inc, Broad Institute and Amyris Biotechnologies Inc. In addition, he has served at several Editorial Boards, including those of Virology, Molecular Biology and Medicine, Molecular and Cellular Bioogy and Journal of Virology; as well as Professional and Advisory Boards, including those of Biotechnology Industry Organization, Pharmaceutical Research and Manufacturers of America and Technology Network, among others. He also holds several awards and honors, such as American Cancer Society Senior Fellowship, Corporate Leadership Award in Science from Irvington Institute, Corporate Leadership Award from National Breast Cancer Coalition and James Madison Medal Award from the Princeton University, among others.
Andreas Oeri	Dr. Andreas Oeri has been Non-Executive Director at Roche Holding AG since 1996. In addition, he acts as Chairman of the Corporate Governance and Sustainability Committee of the Company. From 1997 until 1985, he worked as Assistant Physician in the Surgical Clinic of the Cantonal Hospital (Kantonsspital) in Liestal, the Institute for Physical Medicine of the Cantonal Hospital (Kantonsspital) in Basel, the Surgical Department of the University of Basel and Basel University Orthopedic Hospital. From 1986 until 1988, Dr. Oeri was Acting Senior Physician of the Basel University Orthopedic Hospital. In 1988 he became a Specialist in Orthopedic Surgery (FMH). Since 1988, he has had his own practice for Orthopedic Surgery in Basel. Dr. Oeri completed Medical Studies at Universitaet Basel and holds a Swiss Medical Diploma as well as a Doctorate of Medicine.
Peter Voser	Mr. Peter R. Voser has been Non-Executive Director at Roche Holding AG since March 1, 2011. He is Member of the Remuneration Committee at the Company. He started his career in 1982 by joining the Royal Dutch Shell. He held there various finance and business roles in Switzerland, the United Kingdom, Argentina and Chile. In 1997 he became Group Chief Internal Auditor at the company and in 1999 he was appointed Chief Financial Officer (CFO) of Shell Europe Oil Products. In 2001 he became CFO of the Global Oil Products Business and Member of the Oil Products Executive Committee. Between 2002 and 2004, Mr. Voser acted as CFO and an Executive Committee Member of the Asea Brown Boveri (ABB) Group of Companies. From 2004 and 2009 he held the position of Chief Financial Officer (CFO) and an Executive Director of Royal Dutch Shell. Since 2009 he has been active as Chief Executive Officer of Royal Dutch Shell and since 2010, he has acted as Director of Catalyst. He studied Business Administration at Zuercher Hochschule fuer angewandte Wissenschaften, ZHW (the University of Applied Sciences).
Beatrice Weder di Mauro	Prof. Dr. Beatrice Weder di Mauro has been Non-Executive Director at Roche Holding AG since 2006. In addition, she acts as Member of the Audit Committee of the Company. She studied at Universitaet Basel, Department of Economics, where she gained a Doctorate (Ph.D.) degree in 1993. From 1993 until 1994, Prod. Dr. Weder di Mauro was Post-Doctoral Research Fellow at the University of Basel. From 1994 until 1996, she was Economist at the International Monetary Fund, Washington D.C. From 1996 until 1997, Prof. Dr. Weder di Mauro was Economist at the World Bank, Washington D.C. From 1997 until 1998, she was Research Fellow at the United Nations University, Tokyo. From 1998 until 2001, she was Assistant Professor of Economics at the University of Basel. Since 2001, she has been Professor of Economics at the University of Mainz and since 2004, Prof. Dr. Weder di Mauro has been Member of the German Council of Economic Experts. She was Member of the Board of Macroeconomic Advisors of the Swiss Federation from 2002 until 2004. From 2001 until 2004, she was Member of the Scientific Advisory Board of the Institute for Economic Research (HWWA) in Hamburg. From 2002 until 2004, she was Co-Editor of Applied Economics Quarterly in Berlin. Prof. Dr. Weder di Mauro is Member of the Supervisory Board of ERGO Insurance Group since 2005. Since 2003, she has been Research Fellow at the Center For Economic Policy Research and since 2005, she has been Member of the Steering Committee of the Group: The Macroeconomics of Global Interdependence. She is Member of Committee on International Economics of the Verein fuer Socialpolitik since 2005. Prof. Dr. Weder di Mauro is Research Fellow at the Center for Financial Studies in Frankfurt since 1999, among others.
F. Hoffmann

Basic Compensation

Name	Fiscal Year Total
Severin Schwan	4,000,000
Fritz Gerber	--
Franz Humer	8,953
Bruno Gehrig	400,000
Andre Hoffmann	400,000
Alan Hippe	2,100,000
Stephan Feldhaus	--
Sophie Kornowski-Bonnet	--
Osamu Nagayama	--
John Reed	--
Richard Scheller	--
Urs Jaisli	--
Gottlieb Keller	1,500,000
Silvia Ayyoubi	1,200,000
Roland Diggelmann	647,750
Daniel O'Day	1,575,000
Per-Olof Attinger	--
Pius Baschera	330,000
John Bell	330,000
Paul Bulcke	330,000
William Burns	330,000
Lodewijk de Vink	330,000
Christoph Franz	330,000
DeAnne Julius	360,000
Arthur Levinson	330,000
Andreas Oeri	360,000
Peter Voser	330,000
Beatrice Weder di Mauro	330,000
F. Hoffmann	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Severin Schwan	0	0
Fritz Gerber	0	0
Franz Humer	0	0
Bruno Gehrig	0	0
Andre Hoffmann	0	0
Alan Hippe	0	0
Stephan Feldhaus	0	0
Sophie Kornowski-Bonnet	0	0
Osamu Nagayama	0	0
John Reed	0	0
Richard Scheller	0	0
Urs Jaisli	0	0
Gottlieb Keller	0	0
Silvia Ayyoubi	0	0
Roland Diggelmann	0	0
Daniel O'Day	0	0
Per-Olof Attinger	0	0
Pius Baschera	0	0
John Bell	0	0
Paul Bulcke	0	0
William Burns	0	0
Lodewijk de Vink	0	0
Christoph Franz	0	0
DeAnne Julius	0	0
Arthur Levinson	0	0
Andreas Oeri	0	0
Peter Voser	0	0
Beatrice Weder di Mauro	0	0
F. Hoffmann	0	0

Insider Trading

» Full list on Insider Trading

People: Roche Holding AG (RHHVF.PK)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: